Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Kapoor S, Kaushik VV, Jain R, Rao V, Gharia M
Rheumatology and Therapy, September 2019, Volume 6, Issue 3, pp 451–459
Real-life efficacy and tolerability profile of a similar biologic of adalimumab (ZRC-3197) in patients with inflammatory arthritic conditions
Viswanath V. Kaushik, Rheumatology, Arthritis & Rheumatism Centre, Chennai, Tamilnadu India
Oxford Rheumatology, April/2018/57(3)
Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases
Ashish J Mathew, Arvind Ganapati, Sathish Kumar T1, Ruchika Goel, Sandhya P, Debashish Danda
Journal of The Association of Physicians of India, May/2017/65(5)
Clinical use of ZRC3197 (Adalimumab Biosimilar) in Patients with Inflammatory Arthritis : A Real-life Experience
Banwari Sharma
Journal of The Association of Physicians of India, May/2017/65(5)
Real-life safety profile of biosimilar adalimumab in patients with inflammatory arthritic conditions
V. Kaushik, S. Apparao
Annals of the Rheumatic Diseases, June/2017/76(2)
Real-life patient characteristics and treatment assessments following clinical use of biosimilar adalimumab (ExemptiaTM) in patients with various inflammatory arthritis conditions
A. Badika, HOD Rheumatology, Choithram Hospital and Research Centre, Indore
International Journal of Rheumatic Disease, October/2017/20(1)
A prospective, randomized, double-blind, multicenter, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (ExemptiaTM; ZRC-3197) and adalimumab (Humira®) in patients with rheumatoid arthritis
Rajendrakumar H. Jani, Rajiv Gupta, Girish Bhatia, Gaurav Rathi, Patnala Ashok Kumar, Reena sharma, Uma Kumar, Liyakat A. Gauri, Praveen Jadhav, Girishchandra Bartakke, Vikram Haridas, Dinesh Jain and Sanjeev K. Mendiratta
International Journal of Rheumatic Diseases, Volume 19 | Number 11 | November 2016
Real-life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab biosimilar Patient Registry Data
Sanjiv Kapoor, Viswanath V. Kaushik, Rahul Jain, Vijay K. R. Rao, and Mihir Gharia
ACR Open Rheumatology Journal, Early Access August 12, 2019
Prolonged effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Arvind Chopra, Nagnath Khadke, Manjit Saluja, Toktam Kainifard and Anuradha Venugopalan
Arthritis Rheumatol. 2018; 70 (suppl 10)
Efficacy and safety of an altered dose of biosimilar adalimumab after the initial recommended therapy in patients with ankylosing spondylitis
S. Bandyopadhyay; S. Ghosh, Apollo Gleneagles Hospital, Kolkata, India
International Journal Of Rheumatic Disease, September/2018/Volume 21, Issue S1
Real-life efficacy and tolerability profile of a similar biologic of adalimumab (ZRC-3197) in patients with inflammatory arthritic conditions
Viswanath V. Kaushik, Rheumatology, Arthritis & Rheumatism Centre, Chennai, Tamilnadu India
Oxford Rheumatology, April/2018/57(3)
Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases
Ashish J Mathew, Arvind Ganapati, Sathish Kumar T1, Ruchika Goel, Sandhya P, Debashish Danda
Journal of The Association of Physicians of India, May/2017/65(5)
Switching from Other Biologics to ZRC3197 (Adalimumab Biosimilar) in Patients with Spondyloarthropathy : A Prospective Evaluation from Real-Life Clinical Practice
Sanjiv Kapoor
Journal of The Association of Physicians of India, May/2017/65(5)
Clinical use of ZRC3197 (Adalimumab Biosimilar) in Patients with Inflammatory Arthritis : A Real-life Experience
Banwari Sharma
Journal of The Association of Physicians of India, May/2017/65(5)
Continued effectiveness of a biosimilar adalimumab after stoppage of initial treatment in patients with ankylosing spondylitis
S. Bandyopadhyay, A. Ray, R. N. Sarkar, S. Dash, S. Mondal
Annals of the Rheumatic Diseases, June/2017/76(2)
Real-life safety profile of biosimilar adalimumab in patients with inflammatory arthritic conditions
V. Kaushik, S. Apparao
Annals of the Rheumatic Diseases, June/2017/76(2)
Improvement in disease activity and functional disability following treatment with biosimilar adalimumab in patients with ankylosing spondylitis
VK Rao, A Sudhakar
International Journal of Rheumatic Disease, October/2017/20(1)
Comparison of efficacy of Biosimilar Adalimumab therapy in Ankylosing Spondylitis patients - 6 months Vs 1 year
S. Bandyopadhyay, A. Ray, R. N. Sarkar, S. Dash, S. Mondal
International Journal of Rheumatic Disease, October/2017/20(1)
Real-life patient characteristics and treatment assessments following clinical use of biosimilar adalimumab (ExemptiaTM) in patients with various inflammatory arthritis conditions
A. Badika, HOD Rheumatology, Choithram Hospital and Research Centre, Indore
International Journal of Rheumatic Disease, October/2017/20(1)
Efficacy and Safety of Adalimumab Biosimilar (ExemptiaTM) in Ankylosing Spondylitis
S. Bandyopadhyay, A. Ray, R. Sarkar
International Journal of Rheumatic Diseases, September/2016
Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases
Ashish J Mathew, Arvind Ganapati, Sathish Kumar T1, Ruchika Goel, Sandhya P, Debashish Danda
Journal of The Association of Physicians of India, May/2017/65(5)
Real-life patient characteristics and treatment assessments following clinical use of biosimilar adalimumab (ExemptiaTM) in patients with various inflammatory arthritis conditions
A. Badika, HOD Rheumatology, Choithram Hospital and Research Centre, Indore
International Journal of Rheumatic Disease, October/2017/20(1)
Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases
Ashish J Mathew, Arvind Ganapati, Sathish Kumar T1, Ruchika Goel, Sandhya P, Debashish Danda
Journal of The Association of Physicians of India, May/2017/65(5)
Real-life patient characteristics and treatment assessments following clinical use of biosimilar adalimumab (ExemptiaTM) in patients with various inflammatory arthritis conditions
A. Badika, HOD Rheumatology, Choithram Hospital and Research Centre, Indore
International Journal of Rheumatic Disease, October/2017/20(1)
Use, Safety and Efficacy of ZRC 3197, a Biosimilar Candidate for Reference Adalimumab (Humira®) from a Tertiary Pediatric Rheumatology Centre in India
Manjari Agarwa, Abhay Shivpuri, Sumidha Mittal, Amit Khosla and Sujata Sawhney
Arthritis & Rheumatology, November/2016/68(10)
Reduced Injection Site Pain with Succinate Buffer‑Based Adalimumab Biosimilar (ZRC‑3197) Injection (SUFFER Study): An Observational Study
Mihir Gharia, Sudhakar A, Zydus Biovation, Zydus Cadila Healthcare Ltd.
Indian Journal of Rheumatology, Jun/2019/14
A Case of Relapsing Polychondritis with Stenosis Successfully Controlled with Biosimilar Adalimumab (ZRC‑3197)
Dugar M, Saluja JS, Sudhakar A
Indian J Rheumatol. 2019;14:81-82
A Case of Isotretinoin Therapy‑Refractory Folliculitis Decalvans Treated Successfully with Biosimilar Adalimumab (ExemptiaTM)
Furtado Shireen, A Sudhakar
International Journal of Trichology, Dec/2018/10(5)
Reduced injection site pain with succinate buffer based Adalimumab biosimilar injection (SUFFER Study) : An observational study
Mihir Gharia, Sudhakar A
Indian Journal of Rheumatology, November/2016
Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197
Sanjay Bandyopadhyay, Mukesh Mahajan, Tulsi Mehta, Arun K Singh, Aashini Parikh, Ajit K Gupta, Pankaj Kalita, Mihir Patel, Sanjeev Kumar Mendiratta
Biosimilars. 2015;5:1-18
